Brainsway (NASDAQ:BWAY) Reaches New 1-Year High on Earnings Beat

Shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) reached a new 52-week high on Thursday following a stronger than expected earnings report. The stock traded as high as $17.40 and last traded at $16.60, with a volume of 622702 shares trading hands. The stock had previously closed at $14.98.

The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Brainsway had a return on equity of 13.01% and a net margin of 15.65%.The company had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.54 million.

Brainsway News Summary

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Strong Q2 performance: BrainsWay reported adjusted EPS of $0.14, beating the $0.10 consensus estimate, while revenue rose 35% year over year to a record $17.1 million, above expectations of $16.54 million. The company also reported a 15.68% net margin and 12.28% return on equity. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Raised full-year outlook: Management forecast 2026 revenue of $68 million to $70 million, modestly above the $67.8 million analyst consensus. The improved outlook reinforces expectations for continued growth in BrainsWay’s transcranial magnetic stimulation business. BrainsWay earnings report
• Positive Sentiment: Analysts raised targets: BTIG Research increased its price target from $18 to $20 and maintained a Buy rating. Ladenburg Thalmann also raised its target from $18 to $18.80 and assigned a Buy rating, indicating further potential upside from recent trading levels. BTIG raises BrainsWay price target
• Neutral Sentiment: Momentum near a new high: BWAY recently reached a new 1-year high following the earnings beat, reflecting strong momentum but also potentially increasing profit-taking risk after the rally. Brainsway sets new 1-year high
• Negative Sentiment: Rating downgrade: Zacks Research cut BrainsWay from “strong buy” to “hold,” providing a counterweight to the favorable earnings news and other analysts’ target increases. Zacks downgrade of BrainsWay

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of Brainsway in a report on Friday, July 17th. New Street Research reissued a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 2nd. Weiss Ratings restated a “buy (b-)” rating on shares of Brainsway in a research note on Tuesday, July 21st. Finally, Zacks Research cut Brainsway from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.95.

Institutional Investors Weigh In On Brainsway

Several hedge funds have recently bought and sold shares of BWAY. Ballast Advisors LLC purchased a new stake in Brainsway in the first quarter worth about $55,000. Bank of America Corp DE purchased a new position in shares of Brainsway during the first quarter valued at approximately $206,000. Royal Bank of Canada boosted its position in shares of Brainsway by 84.2% in the 1st quarter. Royal Bank of Canada now owns 15,490 shares of the company’s stock worth $206,000 after purchasing an additional 7,080 shares in the last quarter. Masters Capital Management LLC boosted its position in shares of Brainsway by 65.0% in the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after purchasing an additional 650,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Brainsway by 87.2% in the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after buying an additional 241,560 shares during the last quarter. Institutional investors own 30.11% of the company’s stock.

Brainsway Trading Down 0.8%

The company has a market cap of $660.94 million, a PE ratio of 37.43 and a beta of 1.24. The firm has a 50 day moving average of $15.13 and a two-hundred day moving average of $14.36.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.